Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Portal Hypertension in HBV Cirrhosis
NCT05483894Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of atorvastatin in Portal Hypertension (PH) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Response rate at 12 weeks. Status: unknown.
02
Drugs
atorvastatin
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT05483894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483894.